Journal
CELL CYCLE
Volume 12, Issue 18, Pages 2960-2968Publisher
TAYLOR & FRANCIS INC
DOI: 10.4161/cc.26034
Keywords
TGF-beta; EMT; chemotherapy; drug resistance
Categories
Funding
- Dutch Cancer Society [2011-4964]
- EU [RATHER, COLTHERES]
Ask authors/readers for more resources
The transforming growth factor beta (TGF-beta) pathway acts as a double-edged sword in tumorigenesis. By constraining epithelial cell growth, TGF-beta is a potent tumor suppressor. However, TGF-beta also acts as a key player in the induction of epithelial-to-mesenchymal transition (EMT), thereby enhancing invasiveness and metastasis. Furthermore, TGF-beta signaling has recently been correlated with resistance against both targeted and conventional anticancer agents. Here, we present data demonstrating a role for TGF-beta in chemotherapy resistance in colorectal cancer (CRC). We discuss these results in the context of recent findings indicating TGF-beta signaling as an emerging player in cancer drug resistance.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available